Paper

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Published Mar 30, 2021 · Katherine Emary, T. Golubchik, P. Aley

Lancet (London, England)

467

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

RCT

Large Human Trial

Rigorous Journal

Highly Cited

Study Snapshot

ChAdOx1 nCoV-19 vaccine showed reduced neutralization activity against the B.1.1.7 variant of SARS-CoV-2, but showed efficacy against the B.1.1.7 variant of COVID-19.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

References

Citations